The new effective chemotherapeutic drugs are required urgently for advanced and recurrent
endometrial carcinoma (EC), which is one of the most common gynaecological
tumors among women worldwide. Preclinical studies have shown that
lobaplatin, one of the third-generation
platinum compounds, has possessed powerful anti-
cancer efficacy on a series of
tumors. The purpose of this study is to investigate its effect and molecular mechanism on the growth of
endometrial cancer cell line Ishikawa in vitro and in vivo. The results of cell counting kit-8 (CCK-8) shown that
lobaplatin concentration-dependent inhibited cell proliferations in human
endometrial carcinoma ishikawa cells. Flow cytometry (FCM) assay demonstrated that
lobaplatin affected the survival of
endometrial carcinoma cell by arresting cell cycle at S phase and G2/M phase and inducing apoptosis in dose-dependent manner. Moreover, Western blot analysis also showed that the apoptosis-inducing effects of
lobaplatin was associated with the reduction of Bcl-2 expression while upregulation of cleaved-caspase-3, cleaved-caspase-8, cleaved-caspase-9 and Bax. Meanwhile,
lobaplatin significantly suppressed
tumor growth of human Ishikawa xenograft models and terminal deoxynucleotidyl trans-ferase dUTP nick end labeling confirmed the significant occurrence of
lobaplatin-treated
tumor tissues of apoptosis. Therefore,
lobaplatin could be an effective chemotherapeutic agent for human
endometrial carcinoma and warrants further clinical investigation.